NEUROENDOCRINE TUMORS OF THE STOMACH: CLASSIFICATION, DIAGNOSTICS, TREATMENT (LITERATURE REVIEW)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Neuroendocrine tumors (NET) of the stomach constitute 3-6% of NEO and about 2% of all gastric tumors. NEO of the stomach - a heterogeneous group, including both highly differentiated tumors amenable to endoscopic treatment and characterized by a favorable prognosis, and highly malignant poorly differentiated tumors possessing high metastatic potential and characterized by an extremely aggressive course and poor prognosis. Modern classification of NEO of the stomach is presented; the basic methods of their diagnosis are discussed. It emphasized the treatment of patients with NETs of the stomach can vary from minimally invasive endoscopic techniques (type I and II carcinoids) to aggressive programs of combined and complex treatment (neuroendocrine carcinoid G3).

Full Text

Restricted Access

About the authors

V. M Khomyakov

Email: vladimirkhom@mail.rn
MSROI n.a. P.A. Herzen - Branch of the FSBI NMRRC of RMH PhD, Head of Thoracoabdominal Department Moscow

S. S Pirogov

MSROI n.a. P.A. Herzen - Branch of the FSBI NMRRC of RMH Moscow

A. V Ivanov

MSROI n.a. P.A. Herzen - Branch of the FSBI NMRRC of RMH Moscow

References

  1. Янкин А.В. Нейроэндокринные опухоли желудочно-кишечного тракта. Практическая онкология. 2005:6(4):227-33.
  2. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-59.
  3. Landry C.S., Brock G., Scoggins C.R., McMasters K.M., Martin R.C. 2nd. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann. Surg. Oncol. 2009;16(1):51-60.
  4. Mulkeen A., Cha С. Gastric carcinoid. Curr. Opin. Oncol. 2005;17(1):1-6.
  5. Modlin I.M., Oberg K., Chung D.C., Jensen R.T., de Herder W.W., Thakker R.V., Caplin M., Delle Fave G., Kaltsas G.A., Krenning E.P., Moss S.F., Nilsson O., Rindi G., Salazar R., Ruszniewski P., Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
  6. Burkitt M.D., Pritchard D.M. Pathogenesis and management of gastric carcinoid tumours. Aliment. Pharmacol. Ther. 2006;24(9):1305-20.
  7. Hodgson N., Koniaris L.G., Livingstone A.S., Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg. Endosc. 2005;19(12):1610-12.
  8. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35(Suppl 1):42-55.
  9. Kloppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr. Pathol. 2007;18(3):141-44.
  10. Rindi G., Klöppel G., Alhman H., Caplin M., Couvelard A., de Herder W.W., Erikssson B., Falchetti A., Falconi M., Komminoth P., Körner M., Lopes J.M., McNicol A.M., Nilsson O., Perren A., Scarpa A., Scoazec J.Y., Wiedenmann B.; all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395-401.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies